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Treatment of portal venous thrombosis with
selective superior mesenteric artery infusion of
recombinant tissue plasminogen activator
E. A. Henao, MD, W. Todd Bohannon, MD, and M. B. Silva, Jr, MD, Lubbock, Tex
Portal and mesenteric venous thrombosis is an uncommon condition that is usually treated with systemic anticoagulation.
Catheter-directed thrombolysis via the superior mesenteric artery may be a viable adjunct to treatment of this potentially
morbid condition. We present a case of portal and mesenteric venous thrombosis treated with systemic anticoagulation
and catheter-directed infusion of tissue plasminogen activator via the superior mesenteric artery. (J Vasc Surg 2003;38:
1411-5.)
Mesenteric venous thrombosis is an uncommon condi-
tion, accounting for 5% to 15% of acute mesenteric isch-
emia cases.1 The diagnosis of portal and mesenteric venous
thrombosis can be difficult, because the condition often is
accompanied by nonspecific abdominal symptoms. Sys-
temic anticoagulation with intravenous heparin is the usual
initial treatment for portal and mesenteric venous throm-
bosis. If this is not successful, bowel infarction may occur,
requiring surgical intervention. The addition of thrombo-
lytic therapy to the treatment of portal and mesenteric
venous thrombosis may enhance clearance of thrombus and
hasten improvement of clinical symptoms. We present a
case report of portal and mesenteric venous thrombosis
treated with systemic anticoagulation and catheter-directed
infusion of recombinant tissue plasminogen activator (rt-
PA) via the superior mesenteric artery (SMA).
CASE REPORT
Three weeks after a small bowel resection after reduction of a
strangulated inguinal hernia, a previously healthy 35-year-old man
had progressive abdominal pain, nausea, and vomiting. He had no
fever, blood pressure was normal, and mild tachycardia was noted.
At physical examination there was diffuse tenderness, without
significant rebound or guarding. Laboratory tests showed no leu-
kocytosis or metabolic acidosis. An intravenous contrast material–
enhanced computed tomography (CT) scan of the abdomen and
pelvis demonstrated thrombosis of the portal vein and superior
mesenteric vein (SMV), and small bowel ileus and mesenteric
stranding (Fig 1).
A 5000-U bolus of heparin was administered intravenously,
followed by continuous infusion of 1000 U/h. The patient was
hemodynamically stable, and no peritonitis was noted at abdomi-
nal examination. Therefore, we proceeded with further evaluation
of the mesenteric vasculature with angiography. Selective catheter-
ization of the celiac artery and SMA was performed with a 4F
Simmons 1 Glidecath (Boston Scientific/Medi-Tech, Natick,
Mass). The SMA angiogram revealed an anomalous origin of the
common hepatic artery at the proximal SMA (Fig 2). Delayed
(venous phase) digital subtraction images confirmed thrombosis of
the portal vein and SMV (Fig 3). The catheter was positioned in
the SMA beyond the common hepatic artery origin, and a 2-mg
bolus of rt-PA (alteplase; Genentech, San Francisco, Calif) was
administered. The bolus was followed by continuous rt-PA infu-
sion at 2 mg/h through the 4F catheter. The heparin infusion was
given through the femoral artery sheath, and the rate was reduced
to 500 U/h. The patient was monitored in the intensive care unit
during thrombolytic treatment, and serial abdominal examinations
were performed. Laboratory analysis of hematocrit, platelet count,
prothrombin time, partial thromboplastin time, and fibrinogen
concentration was performed at 6-hour intervals throughout rt-PA
infusion. The abdominal pain improved substantially during the
first 24 hours of thrombolytic therapy.
A follow-up angiogram at 24 hours demonstrated improved
visualization of the portal vein (Fig 4, A). Delayed (venous phase)
digital subtraction angiograms demonstrated improved filling of
the primary, secondary, and tertiary branches of the SMV. rt-PA
infusion was continued at 2 mg/h for an additional 24 hours. After
a total 48 hours of thrombolytic therapy the mesenteric angiogram
with delayed venous images showed a widely patent portal vein
(Fig 4, B), and the thrombolytic infusion was discontinued. The
abdominal pain had completely resolved. Systemic anticoagulation
was achieved through a peripheral intravenous infusion of heparin
and oral warfarin therapy. A follow-up CT scan demonstrated no
evidence of portal or SMV thrombosis (Fig 5). The patient was
discharged with oral anticoagulation therapy once therapeutic
prothrombin time was achieved. There was no evidence of inher-
ited hypercoagulability at subsequent laboratory investigation.
Hypercoagulable studies performed included screening for anti-
thrombin III deficiency, factor V Leyden, protein C and protein S
deficiency, hyperhomocysteinemia, lipoprotein A, and antiphos-
pholipid antibody.
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DISCUSSION
Mesenteric and portal vein thrombosis is an uncom-
mon condition that can occur with cirrhosis, malignant
neoplasia, intra-abdominal infection or inflammation, co-
agulation defects, myeloproliferative disorders, trauma, or
previous abdominal operations.2 Because mesenteric ve-
nous thrombosis often is accompanied by nonspecific ab-
dominal symptoms, the diagnosis can be difficult to deter-
mine. In patients without an acute surgical abdomen,
systemic anticoagulation with heparin and supportive care
is the initial treatment. Operative intervention is reserved
for patients in whom the clinical course is complicated by
progressive bowel ischemia or perforation.
The standard initial treatment for venous thrombosis,
regardless of the vascular bed, has been systemic anticoag-
ulation. In theory, this is supposed to prevent further
thrombosis and thrombus propagation. Thrombolytic
therapy with active clot dissolution may be more effective
than traditional treatment of venous thrombosis with anti-
coagulation and clot stabilization. Various routes of admin-
istration of thrombolytic therapy for treatment of mesen-
teric venous thrombosis have been described in the medical
literature. The Table lists various approaches used to treat
portal and mesenteric venous thrombosis with thrombo-
lytic agents, mechanical thrombectomy devices, or combi-
nation therapy. Systemic administration of urokinase,2,3
t-PA,4 and streptokinase5 has been reported. A transjugu-
lar-transhepatic approach to thrombolytic delivery into the
Fig 1. CT scan demonstrates portal venous thrombosis (arrow).
Fig 2. Selective superior mesenteric artery catheterization demon-
strates anomalous origin of replaced common hepatic artery from
proximal superior mesenteric artery.
Fig 3. Initial selective digital subtraction mesenteric angiogram
with delayed venous phase image confirms portal and mesenteric
venous thrombosis.
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portal venous system has been successfully used to clear
portal and SMV thromboses.6-9 In addition, a transjugular-
intrahepatic portosystemic shunt has been placed for access
to the mesenteric venous system to perform thrombolysis
and mechanical venous thrombectomy.8,9 A percutaneous
transhepatic approach has also been described.10,11
Whereas these transhepatic approaches are successful in
clearance of thrombus in the larger mesenteric veins, they
may not be ideal in addressing thrombus in the smaller
secondary and tertiary venous branches. As in our patient,
transarterial infusion, in theory, would be more effective
because it enables the thrombolytic agent to permeate the
capillaries and small venules.12 Thrombolysis will then
progress to the larger veins and restore normal vascular bed
perfusion.12 With selective catheterization of the SMA and
renal arteries, this transarterial route of thrombolytic ad-
ministration has been used in clearance of mesenteric13 and
renal14 vein thromboses. The transarterial infusion avoids
the potential bleeding complications that may result from
parenchymal liver puncture. A combined approach of per-
cutaneous transhepatic mechanical thrombectomy fol-
lowed by transarterial infusion of rt-PA has also been de-
scribed.15
Most previously reported catheter-directed portal and
mesenteric venous thrombolysis has been described using
urokinase.9,12,13,16-18 In 1991 Meis19 used a systemic bo-
lus of 100 mg of rt-PA followed 48 hours later by an
intra-arterial bolus of 50 mg via the SMA, infused over 90
minutes. In contrast, our patient received continuous cath-
eter-directed infusion of rt-PA, with a significantly smaller
initial bolus. Urokinase was not commercially available at
the time of our patient’s treatment. We used rt-PA, and
there may be some potential advantages compared with
urokinase. Clearance of alteplase is mediated primarily by
the liver, which may afford use of higher doses in the
mesenteric circulation. In vitro studies with t-PA have
shown a higher thrombolytic rate, less plasminogen activa-
Fig 4. A, Follow-up angiogram at 24 hours demonstrates im-
proved visualization of portal vein (arrow). B, t-PA infusion was
continued for an additional 24 hours, and completion angiogram
shows a widely patent portal vein (arrow).
Fig 5. CT scan after thrombolysis demonstrates clearance of
thrombus from portal vein (arrow).
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tion, less 2-antiplasmin consumption, and less fibrinogen
breakdown, when compared with urokinase.20 Infusion
time is shorter and less expensive in catheter-directed
thrombolysis compared with urokinase therapy.21
Our patient did not have a primary hypercoagulable
state, and the inciting event for the mesenteric venous
thrombosis was hypothesized to be the strangulated small
bowel, which required resection. With the addition of
rt-PA to the traditional regimen of systemic anticoagula-
tion, we observed an expeditious resolution of the symp-
toms and significant improvement in the mesenteric venous
thrombus burden. Thrombolytic therapy was continued on
the basis of a number of factors, including radiographic
evidence of progressive thrombolysis, improving physical
findings on clinical evaluation, and satisfactory evidence of
limited systemic fibrinolytic effect. If the clinical findings
worsened or the patient demonstrated evidence of systemic
fibrinolysis or manifested bleeding complications, lytic
therapy would have been halted. Although systemic anti-
coagulation with heparin is the most common therapy for
acute portal and mesenteric venous thrombosis, catheter-
directed thrombolysis with rt-PA through the SMA may be
a viable adjunct to treatment of this potentially morbid
condition.
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